FDA approves rivanetin as the first-line treatment for lung cancer.

Published Date: 08 Mar 2024

For NSCLCs with EGFR exon 20 insertion mutations, a bispecific medication receives complete approval.

Read Full News

Latest News

‘Modest’ Differences in OAT Should Not Obscure Benefits

Methadone may be linked to a lower risk for death than buprenorphine-naloxone in the short term, but after an overdose, either opioid agonist therapy is better than none.

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

(This Aug 27 story has been republished, with no changes to text.)

Alzheimer's Blood Test Gets FDA Clearance

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

Less Seniors Taking Inappropriate Cognitive Meds

Older adults with cognitive disorders who use inappropriate medications linked to adverse cognitive effects are more likely to have poor mental health-related quality of life.

US Health Department Seeks Public Feedback on Vaccine Guidelines After Trump Order

The U.S. health department said on Friday it was seeking public feedback on federal vaccine recommendations, including how they ⁠are categorized and communicated, after...

Cognitive Therapy Boosts Brain Function in Schizophrenia

Structured cognitive remediation therapy helps boost brain activity, working memory, and quality of life and reduce severity of symptoms in patients with schizophrenia, a trial shows.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Latest News

Methadone may be linked to a lower risk for death than buprenorphine-naloxone in the short term, but after an overdose, either opioid agonist therapy is better than none.

(This Aug 27 story has been republished, with no changes to text.)

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

Older adults with cognitive disorders who use inappropriate medications linked to adverse cognitive effects are more likely to have poor mental health-related quality of life.

The U.S. health department said on Friday it was seeking public feedback on federal vaccine recommendations, including how they ⁠are categorized and communicated, after...

Structured cognitive remediation therapy helps boost brain activity, working memory, and quality of life and reduce severity of symptoms in patients with schizophrenia, a trial shows.

News All Time

Study Questions How Prostate Cancer Focal Therapy Is Being Used

Half of procedures occurred in settings not supported by guidelines

Whole Foods Recall; RFK Jr.'s Voting Problem; Glass Particles in Biosimilar

Health news and commentary gathered by MedPage Today staff

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

News, features, and commentary about cancer-related issues

Genomic Newborn Screening Could Identify Childhood Cancer Predisposition

Testing could give doctors an early start on life-preserving cancer treatments

SBRT Misses the Mark in Prostate Cancer Trial

No improvement over intensity-modulated RT in urinary symptoms after 2 years, DFS after 3 years

What Caused This Young Man's Bladder Cancer

Occupational exposure, family history make tempting hypotheses

Dramatic Increase in Active Surveillance Use for Prostate Cancer

Soared past 90% in VA system for low-risk disease, to 61% for favorable intermediate-risk disease

Melanoma Patient on Immunotherapy Develops Severe Dermatitis

Clinicians faced with presumed dermatologic AEs urged to consider all differentials

Early Sugar Exposure and Cancer Risk; Melanoma Vaccine Win; 'Antifreeze' for CAR-T

News, features, and commentary about cancer-related issues

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

Freeman’s Lobotomy to Deep Brain Stimulation: What Changed?

The history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

Preschool-aged children exposed to screens for extended daily periods face elevated prevalence of sleep disturbances.

US Mental Health Treatment Rates Rise But Gaps Persist

Treatment rates for US adults with psychiatric disorders are modestly higher than in previous decades, but only a third receive minimally adequate care, new research shows.

Cognitive Bias Modification App Fosters Alcohol Avoidance

An Australian-designed smartphone app uses personalized cognitive bias modification to help users reduce or avoid alcohol consumption.

Schizophrenia: Nighttime Light Tied to Metabolic Dysfunction

Higher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Consistently low PSA levels failed to signal metastasis

Recommended News For You

Nonpharmacologics May Reduce Anxiety, Depression in SUD

Insurance Claim Denials for Preventive Care More Common in At-Risk Patients

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.

Clinical trial is testing whether heavy lifting could combat cancer side effects

Headlines About Doc Who 'Catches' Patient's Cancer Are Popping Up Again

FDA approves rivanetin as the first-line treatment for lung cancer.

Routine breast cancer screening can bring better outcomes for patients

Recommended Articles For You

Lymphomatoid Papulosis: What You Need to Know 

Critical Care Challenges in Oncologic Emergencies 

Emerging Therapies Using Immune-Engineered Cancer Eradication Platforms 

Clinical Frameworks in Oncology and Quality Improvement 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries

2.

EVP Beats Cisplatin for Resectable MIBC

3.

EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer

4.

Oncologist on Hantavirus Cruise; Bile Duct Cancer Drug OK'd; Untreated Lung Cancers

5.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

1.

Innovative Breakthroughs in Hematology for Modern Medicine

2.

Altered Marrow Cell-Production Dynamics During Chronic Hematologic Stress

3.

Hematopoietic Stem Cell Clonal Dynamics Across the Lifespan

4.

Work Function in Hematologic Disease: Mechanisms, Clinical Implications, and Emerging Perspectives

5.

Adaptive Rehabilitation Frameworks for Complex Cancer Survivorship

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Should We Use DARA Up Front As First-Line Therapy in MM?

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

3.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

4.

Thromboprophylaxis In Medical Settings

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot